Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.
High-dose antithrombin III therapy had no effect on 28-day all-cause mortality in adult patients with severe sepsis and septic shock when administered within 6 hours after the onset.
High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial
High-dose antithrombin III therapy had no effect on 28-day all-cause mortality in adult patients with severe sepsis and septic shock when administered within 6 hours after the onset and was associated with an increased risk of hemorrhage when administered with heparin.
Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial
- I. Pabinger, B. Brenner, U. Kalina, S. Knaub, A. Nagy, H. Ostermann
- MedicineJournal of Thrombosis and Haemostasis
- 1 April 2008
PCC treatment serves as an effective rapid hemorrhage control resource in the emergency anticoagulant reversal setting and more widespread availability of PCC is warranted to ensure its benefits in appropriate patients.
Antithrombin, heparin, and heparan sulfate
The results of a recent phase 3 clinical trials with high-dose antithrombin in sepsis suggested a beneficial effect in patients who did not concomitantly receive heparin, thereby generating new challenges in the understanding of interactions between antithromabin and heparIn or hepar in-like proteoglycans.
Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia
- F. Peyvandi, S. Haertel, S. Knaub, P. Mannucci
- Medicine, BiologyJournal of Thrombosis and Haemostasis
- 1 July 2006
Hemparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation, and fondaparinux as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins.
Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
- H. Ostermann, S. Haertel, S. Knaub, U. Kalina, K. Jung, I. Pabinger
- Medicine, BiologyThrombosis and Haemostasis
- 1 October 2007
Rapid PCC infusion produced prompt sustained increases in coagulation factors and anticoagulant proteins with no clinical evidence of thrombosis or viral transmission.
Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A
- A. Tiede, J. Oldenburg, T. Lissitchkov, S. Knaub, J. Bichler, M. Manco-Johnson
- Medicine, BiologyHaemophilia
- 1 May 2016
Haemophilia A is treated with FVIII, either prophylactically or on demand. Prophylaxis is the gold standard in children and evidence is accumulating in adults.
The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics
For the first time, recombinant human clotting factor VIII produced in a human host cell line is available and may lead to immunogenic reactions and the development of inhibitors against rhFVIII.
First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction…
Development of neutralizing inhibitors against factor VIII (FVIII) is a major complication of haemophilia A treatment.
The first recombinant FVIII produced in human cells – an update on its clinical development programme
Human‐cl rhFVIII is efficacious and safe in the prevention and treatment of bleeding episodes and that none of the treated patients developed inhibitors or allergic reactions thus far, and pharmacokinetic data with a mean half‐life of 17.1 h allow personalized prophylaxis with the chance of fewer infusions.